Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545452 | 1.00 | PDK2 (0.44) | PDK2FKBP1AALDH1A1LOXMMP2 | |
| SCHEMBL3552619 | 0.93 | FKBP1A (0.50) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3552618 | 0.93 | FKBP1A (0.50) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3547320 | 0.88 | MMP2 (0.39) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3547321 | 0.88 | MMP2 (0.39) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3553703 | 0.88 | FKBP1A (0.42) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3553701 | 0.88 | FKBP1A (0.42) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3544529 | 0.87 | FKBP1A (0.44) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3544530 | 0.87 | FKBP1A (0.44) | PDK2FKBP1AALDH1A1MMP2ANPEP | |
| SCHEMBL3547715 | 0.84 | FKBP1A (0.44) | PDK2FKBP1AALDH1A1LOXKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | PDK2 2445/4885FKBP1A 3069/4885ALDH1A1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.